Schmedt N, et al. - Researchers performed a cohort study with a nested case-control analysis based on the InGef database between November 2011 and December 2016 to examine whether the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors was associated with an increased risk of fractures of the upper or lower limbs in patients with type 2 diabetes. Participants in the study were patients with type 2 diabetes who initiating treatment with or switching to or adding a new class of a non-insulin antidiabetic drug. They involved patients with a hospital or ambulatory diagnosis of fractures of the upper or lower limbs and matched to up to 40 randomly sampled controls. In patients with type 2 diabetes, SGLT-2 inhibitors and other antidiabetic drug classes were not correlated with an increased risk of fractures of the upper or lower limbs vs DPP-4 inhibitors.